National Comprehensive Cancer Network (NCCN) Decision Support Tool for Patients With NSCLC

NCT03982459 | Completed Results

• 1 other identifier: 14655
• Study Type: interventional
• Target: 76
• Locations: 1 country
• Sites: 1

Brief Summary

This study involves the evaluation of a decision support tool, based on the patient version of the NCCN guidelines, for the non-small cell lung cancer patient population.

Conditions

Non-small Cell Lung Cancer

Outcome Measures

Primary Outcomes (1)

• Percentage of Participants Reporting Quality of Care on Selected National Comprehensive Cancer Center (NCCN) Recommendations

  Participants explored individually tailored decision trees derived from the NCCN guidelines. Six benchmarks of quality care derived from the guidelines were evaluated: (1) documented smoking cessation counseling in active smokers, (2) adjuvant chemotherapy for patients with stage IB to IIB NSCLC after surgery, (3) pathologic mediastinal staging in patients with stage III NSCLC before surgery, (4) pathologic mediastinal staging in patients with stage III NSCLC before nonsurgical management, (5) definitive chemoradiotherapy for patients with stage III NSCLC not undergoing surgery, and (6) molecular testing for epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) alterations for patients with stage IV NSCLC. Because the decision trees were tailored, not all participants evaluated all 6 benchmarks. The percentage of participants who interacted with each benchmark and demonstrated quality of care will be reported.

  1 Day

Secondary Outcomes (6)

• Median Change in Decisional Conflict Scale (DCS) Score Over Time

  1 Day

• Median Scores by Item on the Satisfaction With Health Care Decision Questionnaire

  1 Day

• Number of Participants by Response on the Decisional Support Preference Questionnaire (DMPQ)

  1 Day

• Median Total Score on the Quality of Life by the Functional Assessment of Cancer Therapy-Lung (FACT-L) Questionnaire

  1 Day

• Median Scores on the National Comprehensive Cancer Network-Functional Assessment of Cancer Therapy Lung Symptom Index (NFLSI-17)

  1 Day

Study Arms (1)

Decision support tool

EXPERIMENTAL

Participants receive training in use of a decision support tool by a trained coordinator.

Behavioral: Decision support tool

Interventions

Decision support tool BEHAVIORAL

Internet-Based, interactive decision support tool

Decision support tool

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Over age of 18
• Able to provide informed consent
• Able to use a web-based interface
• Histologically proven or clinically apparent diagnosis of non-small cell lung cancer
• Newly diagnosed, with new primary occurrence of NSCLC, or diagnosed with a new recurrence or new progression of existing disease, and not yet treated for the new problem
• Being seen in consultation at thoracic oncology clinics

You may not qualify if:

• Unable to fill out questionnaires
• Already treated for the current diagnosis of a new primary occurrence of NSCLC, or already treated for the new recurrence or new progression of existing disease

Sponsors & Collaborators

• University of California, San Francisco: lead
• National Comprehensive Cancer Network: collaborator

Study Sites (1)

University of California, San Francisco

San Francisco, California, 94143, United States

Location

Related Publications (1)

• Wu SY, Lazar AA, Gubens MA, Blakely CM, Gottschalk AR, Jablons DM, Jahan TM, Wang VEH, Dunbar TL, Wong ML, Chan JW, Guthrie W, Belkora J, Yom SS. Evaluation of a National Comprehensive Cancer Network Guidelines-Based Decision Support Tool in Patients With Non-Small Cell Lung Cancer: A Nonrandomized Clinical Trial. JAMA Netw Open. 2020 Sep 1;3(9):e209750. doi: 10.1001/jamanetworkopen.2020.9750.

  PMID: 32997124 BACKGROUND

MeSH Terms

Conditions

Carcinoma, Non-Small-Cell Lung

Condition Hierarchy (Ancestors)

Carcinoma, Bronchogenic; Bronchial Neoplasms; Lung Neoplasms; Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms by Site; Neoplasms; Lung Diseases; Respiratory Tract Diseases

Results Point of Contact

• Title: Dr. Sue Yom, MD
• Organization: University of California, San Francisco

sue.yom@ucsf.edu

415-353-7175

Study Officials

• Sue Yom, MD, PhD

  University of California, San Francisco

  PRINCIPAL INVESTIGATOR

Publication Agreements

• PI is Sponsor Employee: Yes
• Restrictive Agreement: No

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: SUPPORTIVE CARE
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 27, 2019
• First Posted: June 11, 2019
• Study Start: February 1, 2015
• Primary Completion: September 1, 2017
• Study Completion: September 1, 2018
• Last Updated: January 9, 2025
• Results First Posted: January 9, 2025

Record last verified: 2024-10

Data Sharing

• IPD Sharing: Will share
• Access Criteria: Requests for datasets should be sent to the Principal Investigator for review and approval for dissemination.

Locations

US (1)